多价免疫球蛋白早期治疗SARS-CoV-2感染相关急性呼吸窘迫综合征的随机对照试验(ICAR试验):研究方案
ICAR试验是一项III期双盲、随机、多中心、平行组、对照研究,评估静脉注射免疫球蛋白(IVIG)在需要机械通气的COVID-19相关ARDS住院患者中的疗效与安全性。
要点
- ICAR试验评估IVIG对COVID-19相关ARDS机械通气患者的疗效与安全性。
- 主要结局为第28天无呼吸机天数,次要结局包括器官衰竭、肺损伤评分、不良事件、ICU住院时长、总住院时长、90天功能结局和90天生存率。
核心结论
- ICAR试验旨在研究IVIG对COVID-19相关ARDS的作用,预期可提高生存率并缩短机械通气持续时间。
研究设计与样本
- III期双盲、随机、多中心、平行组、同期对照研究,采用序贯设计。
- 研究对象为需要机械通气的COVID-19住院患者。
- 治疗组连续4天输注多价免疫球蛋白,安慰剂组输注等体积0.9%氯化钠溶液相同天数。
关键数值与推荐
- 主要结局为第28天无呼吸机天数。
- 次要结局包括第14天和第28天按SOFA评分的器官衰竭、第14天和第28天肺损伤评分、IVIG 3级或4级不良事件发生、ICU住院时长、总住院时长、第90天以ADL和IADL量表定义的功能结局以及90天生存率。
- 样本量计算基于90%把握度、双侧α=0.05、效应量0.67。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As of mid-June 2020, 7,500,000 people were infected with SARS-CoV-2 worldwide and 420,000 people died, mainly from coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS). COVID-19-related ARDS is subject to a mortality rate of 50% and prolonged period of mechanical ventilation, with no specific pharmacological treatment currently available (Infection au nouveau Coronavirus (SARS-CoV-2), COVID-19, France et Monde. https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19 ). Because of its immunomodulatory action, we propose to evaluate the efficacy and safety of intravenous immunoglobulin (IVIG) administration in patients developing COVID-19-related ARDS. METHODS: The trial is a phase III double-blind, randomized, multicenter, parallel group, concurrent, controlled study in hospitalized participants with COVID-19 requiring mechanical ventilation using a sequential design. Participants in the treatment group will receive infusions of polyvalent immunoglobulin for 4 consecutive days, and the placebo group will receive an equivalent volume of sodium chloride 0.9% for the same duration. The primary outcome is the number of ventilator-free days up to the 28th day. Secondary objectives are to evaluate the effect of IVIG on (1) organ failure according to the Sequential Organ Failure Assessment (SOFA) score at 14 and 28 days, (2) lung injury score at 14 and 28 days, (3) the occurrence of grade 3 or 4 adverse events of IVIG, (4) length of intensive care unit (ICU) stay, (5) length of hospital stay, (6) functional outcomes at day 90 defined by the activities of daily living and instrumental activities of the daily living scales, and (7) 90-day survival. One hundred thirty-eight subjects will be randomized in a 1:1 ratio to IVIG or placebo groups (69 in each group), considering 90% power, alpha level 0.05 (two sides), and 0.67 effect size level. DISCUSSION: The ICAR trial investigates the effect of IVIG in COVID-19-related ARDS. We expect an increase in the survival rate and a reduction in the duration of mechanical ventilation, which is associated with significant morbidity. TRIAL REGISTRATION: EudraCT 2020-001570-30. ClinicalTrials.gov NCT04350580 . Registered on 17 April 2020.
引用
- Mazeraud A, Gonçalves B, Aegerter P, et al. Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial. Trials. 2021. PMID: 33648563. doi:10.1186/s13063-021-05118-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。